Compare Nuwellis Inc (NUWE) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Charles Schwab Corporation Common Stock — how do they compare? Nuwellis Inc trades at $2.94 (market cap $1.09M), while Charles Schwab Corporation Common Stock trades at $100.04 (market cap $178.33B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 163605.5× Nuwellis Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | SCHW | |
|---|---|---|
Market Cap | $1.09M | $178.33B |
Sector | Technology | Financials |
52-Week High | $527.46 | $107.21 |
52-Week Low | $2.80 | $85.35 |
Enterprise Value | -$722.58K | — |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $3.00, up 5.26% over 24 hours, following a recent 35:1 reverse stock split effective June 26, 2026. The stock shows a bearish technical signal with all moving averages indicating sell. Fundamentally, the company reported a net loss of $17.52M in 2025, with negative profit margins, though revenue grew to $8.27M. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and new patents offer growth potential. Key risks include negative ROE, reliance on financing, and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid financial headwinds.
Charles Schwab (SCHW) trades at $99.96, down 1.58% on the day, amid strong fundamentals including a 37.99% net income margin and 21.79% ROE. The stock exhibits a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Recent Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.53 estimated, driven by record revenue and client asset growth. Analyst consensus is bullish with a $120 price target, reflecting 20% upside potential.
Outlook remains positive given consistent earnings beats and robust cash flow, though risks include interest rate sensitivity and competitive pressures. The stock's current valuation at a P/E of 20.39 appears reasonable relative to growth, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
